European Medical Journal2d
IL-33 Inhibition Shows Promise in High-Risk COPD
MD: IL-33 inhibition with tozorakimab may offer clinical benefits in patients with COPD at high risk of exacerbations.
Supreme Court upholds FDA’s rejection of fruit-flavored vape liquids
Companies sued the Food and Drug Administration, saying the agency unfairly shifted its standards for approving e-cigarette liquids popular with teens.